UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000028709
Receipt number R000032761
Scientific Title Comparison of drug efficacy between linaclotide and lubiprostone in constipation-predominant irritable bowel syndrome patients
Date of disclosure of the study information 2017/10/01
Last modified on 2019/01/10 11:47:32

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparison of drug efficacy between linaclotide and lubiprostone in constipation-predominant irritable bowel syndrome patients

Acronym

A clinical trial about laxative products for constipation-predominant irritable bowel syndrome

Scientific Title

Comparison of drug efficacy between linaclotide and lubiprostone in constipation-predominant irritable bowel syndrome patients

Scientific Title:Acronym

A clinical trial about laxative products for constipation-predominant irritable bowel syndrome

Region

Japan


Condition

Condition

constipation-predominant irritable bowel syndrome

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

To compare drug efficacy of lubiprostone and linaclotide in constipation-predominant irritable bowel syndrome patients

Basic objectives2

Others

Basic objectives -Others

To evaluate association of drug efficacy with gene polymorphisms and serum cytokines

Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Reduction of GSRS scores and SF-8 scores two weeks after starting medication

Key secondary outcomes

Association of drug efficacy with gene polymorphisms and serum cytokines


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

taking lubiprostone once per day for two weeks

Interventions/Control_2

taking linaclotide once ot two times per day for two weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

The patients diagnosed as constipation-predominant irritable bowel syndrome according to ROME 4 and who don't take lubiprostone either linaclotide

Key exclusion criteria

systemic inflammatory disease, malignancy disease, history of abdominal surgery

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Akiko Shiotani

Organization

Kawasaki Medical School

Division name

Gastroenterology

Zip code


Address

577 Matsushima Kurashiki city Okayama

TEL

086-462-1111

Email

shiotani@med.kawasaki-m.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Akiko Shiotani

Organization

Kawasaki Medical School

Division name

Gastroenterology

Zip code


Address

577 Matsushima Kurashiki city Okayama

TEL

086-462-1111

Homepage URL


Email

shiotani@med.kawasaki-m.ac.jp


Sponsor or person

Institute

Kawasaki Medical School

Institute

Department

Personal name



Funding Source

Organization

Kawasaki Medical School

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor

Handa clinic for Internal Medicine

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

川崎医科大学附属病院(岡山県)


Other administrative information

Date of disclosure of the study information

2017 Year 10 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 07 Month 01 Day

Date of IRB


Anticipated trial start date

2017 Year 10 Month 01 Day

Last follow-up date

2019 Year 03 Month 31 Day

Date of closure to data entry

2019 Year 03 Month 31 Day

Date trial data considered complete

2019 Year 03 Month 31 Day

Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 08 Month 17 Day

Last modified on

2019 Year 01 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032761


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name